Nine analysts set USD 24.71 target for MeiraGTx stock

Published on 10/17/2026 at 18:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 321.43 million in second-quarter 2026. MGTX stock traded at USD 9.28 on October 16, 2026, down 6.17 percent on Nasdaq.

Targets and dates guide trading

Nine analysts assigned a USD 24.71 average target on October 2, 2026.
Second-quarter 2026 revenue reached USD 321.43 million.
MeiraGTx stock traded at USD 9.28 at 4:00 p.m. ET on October 16, 2026, down 6.17 percent versus the prior Nasdaq close.
MarketBeat expects third-quarter results on November 12, 2026.

MGTX, KYG596651029, Illustration mit AI erstellt.

Nine analysts set a USD 24.71 average 12-month target for MeiraGTx, placing the consensus 166.27 percent above the stock's USD 9.28 Nasdaq price. MarketBeat reported the consensus on October 2, 2026. At the Nasdaq close on October 16, 2026, MGTX last stood at USD 9.28 at 4:00 p.m. ET, down 6.17 percent versus the prior Nasdaq close.

Second-quarter revenue reached USD 321.43 million

MeiraGTx reported USD 321.43 million in revenue for the second quarter ended June 30, 2026, compared with USD 0.70 million expected by analysts. Adjusted earnings per share came to USD 1.71, beating the USD 0.46 per-share loss consensus by USD 2.17, according to MarketBeat. The figures make the upcoming reporting date more important than the headline target alone.

Price position on October 16

MeiraGTx traded between USD 9.25 and USD 9.75 during the October 16 session, with a volume of 544,573 shares against an average of 782,312. Its 52-week range was USD 6.62 to USD 15.35, leaving the stock 39.54 percent below the high and 40.18 percent above the low.

On September 23, 2026, MeiraGTx appointed Alan M. Sebulsky as a Class I director and added him to its Science and Technology Committee, according to StockTitan.

Valuation and November date

MeiraGTx had a market capitalization of USD 891.3 million and a price-to-earnings ratio of 13.07 on October 16, 2026. The company pays no dividend yield in the quoted market data. MarketBeat estimates third-quarter results for November 12, 2026, before the market opens, with a revenue consensus of USD 6.95 million and an adjusted earnings-per-share estimate of minus USD 0.46.

Comparison with peers

MeiraGTx (Nasdaq, USD): minus 6.17 percent, P/E 13.07, market capitalization USD 891.3 million.

CRISPR Therapeutics (Nasdaq, USD): minus 4.41 percent, P/E minus 10.35, market capitalization USD 4.8 billion.

Editas Medicine (Nasdaq, USD): minus 3.69 percent, P/E minus 3.14, market capitalization USD 360.9 million.

Stock position and valuation

The latest session put MeiraGTx below its 52-week midpoint while the consensus target remained materially higher than the market price. The next result date gives investors a defined calendar point for testing whether the second-quarter revenue and earnings figures were repeatable.

The further course of trading is shown by the continuously updated real-time quote of MeiraGTx stock.